Lucentis Europska Unija - hrvatski - EMA (European Medicines Agency)

lucentis

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - Луцентис prikazan kod odraslih za liječenje неоваскулярной (vlažna) senilne makularne degeneracije (amd)liječenje vida zbog хориоидальной неоваскуляризации (ХНВ)poremećaje vida zbog dijabetes pomagala макулярного edema (ДМО)poremećaje vida zbog макулярного edema sekundarne okluzije ретинальных vena (branch ili središnji glr glr).

Byooviz Europska Unija - hrvatski - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ximluci Europska Unija - hrvatski - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio Europska Unija - hrvatski - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ikervis Europska Unija - hrvatski - EMA (European Medicines Agency)

ikervis

santen oy - ciklosporin - bolesti rožnice - ophthalmologicals - liječenje teške keratitisa u odraslih bolesnika s suho oko bolesti, što je oplemenjen usprkos suza zamjene.

Lapovis plus 50 mikrograma/ml + 5 mg/ml kapi za oko, otopina Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

lapovis plus 50 mikrograma/ml + 5 mg/ml kapi za oko, otopina

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - latanoprost timololmaleat - kapi za oko, otopina - 0,05 mg/ml + 5 mg/ml - urbroj: jedan ml otopine sadrži 50 mikrograma latanoprosta i 5 mg timolola (u obliku timololmaleata)

Unilat 50 mikrograma/ml kapi za oko, otopina Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

unilat 50 mikrograma/ml kapi za oko, otopina

unimed pharma spol. s r.o., orieskova 11, bratislava, slovačka - latanoprost - kapi za oko, otopina - 50 mikrograma/ml - urbroj: 1 ml otopine sadrži 50 mikrograma latanoprosta

Xalatan 50 mikrograma/ml kapi za oko, otopina Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

xalatan 50 mikrograma/ml kapi za oko, otopina

upjohn eesv, rivium westlaan 142, capelle aan den ijssel, nizozemska - latanoprost - kapi za oko, otopina - 50 mikrograma/ml - urbroj: 1 ml otopine sadrži 50 mikrograma latanoprosta